A study funded by the National Institutes of Health (NIH) has determined that the long-term use of the type 2 diabetes drug Actos (pioglitazone) may be associated with an increased risk of bladder cancer.
The study, which was published in the August 2012 issue of the Journal of National Cancer Institute, looked at patients who take thiazolidinedione (TZD) drugs, such as Avandia or Actos, and concluded that those who take these drugs for an extended period – five or more years – are two to three times more likely to develop bladder cancer than patients who take sulfonylurea-based diabetes medications.
Researchers from the Perelman School of Medicine at the University of Pennsylvania claim this is the first study to compare the risk of TZD drugs to those of sulfonylurea drugs. The study analyzed a British database of 60,000 patients with type 2 diabetes and found that 170 patients per 100,000 taking TZDs could develop bladder cancer. That rate was 60 per 100,000 for those taking the sulfonylurea drugs.
Other studies have linked an increased risk of bladder cancer to Actos. A recent study that appeared in the Canadian Medical Association Journal concluded that patients taking Actos could raise their risks of developing bladder cancer by 22 percent.
Although Actos was banned in Germany and France in 2011, it is still being prescribed in the United States and has spurred thousands of lawsuits against Takeda Pharmaceuticals, the Japan-based manufacturer of the drug.
If you believe that you or a loved one has developed bladder cancer as a result of using Actos, contact the Actos bladder cancer attorneys in Jacksonville at Farah & Farah. Our experienced legal team can explain the ongoing litigation process and clarify what your legal options might be. A free consultation is a phone call away at (800) 533-3555. Call us to find out how we can help you today.